A 55-year-old woman with hepatic cirrhosis (Child-Pugh Class C) and ascites requires analgesia for chronic pain. Which opioid would be the MOST appropriate choice given her altered hepatic metabolism?

Explanation

## Opioid Pharmacokinetics in Hepatic Impairment **Key Point:** In severe hepatic disease (Child-Pugh Class C), fentanyl is the preferred opioid because it produces **inactive metabolites**, avoids the accumulation of renally-cleared active metabolites, and has predictable pharmacokinetics even in decompensated cirrhosis. ### Opioid Metabolism and Hepatic Clearance | Opioid | Hepatic Metabolism | Active Metabolites | Hepatic Impairment Risk | |--------|-------------------|--------------------|------------------------| | Morphine | Phase II conjugation | Morphine-6-glucuronide (active, renally cleared) | **High in decompensated cirrhosis** — M6G accumulates when renal function is impaired (hepatorenal syndrome common in Child-Pugh C) | | Codeine | CYP2D6 O-demethylation | Morphine (active) | **Very high** — unpredictable CYP2D6 activity; risk of toxicity | | Tramadol | CYP2D6 + CYP3A4 | Active metabolites | **Very high** — accumulation, seizure risk, serotonin syndrome; contraindicated in moderate-to-severe hepatic impairment | | Fentanyl | CYP3A4 (hepatic) | **Inactive metabolites (norfentanyl)** | **Lowest among these options** — no active metabolite accumulation; transdermal route bypasses first-pass; preferred in hepatic impairment per current guidelines | ### Why Fentanyl Is Preferred in Child-Pugh Class C 1. **Inactive metabolites:** Fentanyl is metabolized to norfentanyl, which is pharmacologically inactive — no risk of active metabolite accumulation regardless of renal function. 2. **Transdermal route:** Bypasses hepatic first-pass metabolism entirely, providing stable plasma levels without relying on hepatic conjugation capacity. 3. **No CYP2D6 dependence:** Unlike codeine and tramadol, fentanyl does not require CYP2D6 for activation or clearance. 4. **Current guideline support:** AASLD and European Association for the Study of the Liver (EASL) guidelines favor fentanyl (particularly transdermal) over morphine in decompensated cirrhosis, especially when renal impairment coexists. ### Why Morphine Is Problematic in Child-Pugh Class C - Morphine is converted to **morphine-6-glucuronide (M6G)**, a potent active metabolite that is **renally excreted**. - Child-Pugh Class C cirrhosis is frequently complicated by **hepatorenal syndrome or reduced GFR**, causing M6G to accumulate → risk of **prolonged sedation, respiratory depression, and hepatic encephalopathy**. - Phase II glucuronidation, while relatively preserved early in cirrhosis, is significantly impaired in **decompensated (Class C) disease**. ### Why Codeine and Tramadol Are Contraindicated **Codeine:** Requires CYP2D6 conversion to morphine; CYP2D6 activity is unpredictable in cirrhosis → erratic analgesia or opioid toxicity. Avoid in hepatic impairment. **Tramadol:** Extensive CYP2D6/CYP3A4 metabolism; active metabolites accumulate; **major risks include seizures, serotonin syndrome, and CNS depression**. Contraindicated in moderate-to-severe hepatic impairment (KD Tripathi, Essentials of Medical Pharmacology, 8th ed.). **Clinical Pearl:** In **Child-Pugh Class C cirrhosis with ascites** (decompensated disease), the preferred opioid is **fentanyl** — particularly transdermal — because its inactive metabolites do not accumulate in the setting of concurrent renal impairment, which is nearly universal in this population. Morphine should be avoided due to M6G accumulation risk (Harrison's Principles of Internal Medicine, 21st ed.; EASL Clinical Practice Guidelines on Decompensated Cirrhosis). **High-Yield Mnemonic:** **Fentanyl = "Final" safe opioid in decompensated cirrhosis** — Inactive metabolites, No renal accumulation, Avoids CYP2D6, Lowest encephalopathy risk.